Cargando…

A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint

The aim of this study was to evaluate the association between Ferredoxin 1 (FDX1) expression and the prognostic survival of tumor patients and predict the efficacy of immunotherapy response to antitumor drug sensitivity. FDX1 plays an oncogenic role in thirty-three types of tumors, based on TCGA and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Huijiao, Liang, Jiahua, He, Xue, Ye, Huabin, Ruan, Chuangdong, Shao, Hongwei, Zhang, Rongxin, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253061/ https://www.ncbi.nlm.nih.gov/pubmed/37298135 http://dx.doi.org/10.3390/ijms24119182

Ejemplares similares

Oncogenic Role of HMGB1 as An Alarming in Robust Prediction of Immunotherapy Response in Colorectal Cancer
por: Lu, Huijiao, et al.
Publicado: (2022)

Crystal structure and biochemical characterization of Chlamydomonas FDX2 reveal two residues that, when mutated, partially confer FDX2 the redox potential and catalytic properties of FDX1
por: Boehm, Marko, et al.
Publicado: (2015)

Human Mitochondrial Ferredoxin 1 (FDX1) and Ferredoxin 2 (FDX2) Both Bind Cysteine Desulfurase and Donate Electrons for Iron–Sulfur Cluster Biosynthesis
por: Cai, Kai, et al.
Publicado: (2016)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

The role of FDX1 in granulosa cell of Polycystic ovary syndrome (PCOS)
por: Wang, Zhi, et al.
Publicado: (2021)

FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma
por: Zhang, Zeyu, et al.
Publicado: (2021)

Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis
por: Liu, Ziqiang, et al.
Publicado: (2023)

FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis
por: Chen, Gaoxiang, et al.
Publicado: (2023)

Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration
por: Yao, Yimin, et al.
Publicado: (2023)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model
por: Zhang, Xue, et al.
Publicado: (2020)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma
por: Lu, Hanwen, et al.
Publicado: (2022)

FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response
por: Zhang, Guangying, et al.
Publicado: (2023)

Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer
por: Xiao, Chen, et al.
Publicado: (2022)

FDX1-dependent and independent mechanisms of elesclomol-mediated intracellular copper delivery
por: Zulkifli, Mohammad, et al.
Publicado: (2023)

FDX1 regulates cellular protein lipoylation through direct binding to LIAS
por: Dreishpoon, Margaret B., et al.
Publicado: (2023)

FDX1 regulates cellular protein lipoylation through direct binding to LIAS
por: Dreishpoon, Margaret B., et al.
Publicado: (2023)

Lipoylation is dependent on the ferredoxin FDX1 and dispensable under hypoxia in human cells
por: Joshi, Pallavi R., et al.
Publicado: (2023)

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Ribas, Antoni, et al.
Publicado: (2020)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas
por: Zhu, HuaXin, et al.
Publicado: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
por: van der Westhuizen, Andre, et al.
Publicado: (2022)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Corrigendum: Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma
por: Lu, Hanwen, et al.
Publicado: (2023)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells
por: Martins, Christina, et al.
Publicado: (2022)

Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma
por: Jiang, Aimin, et al.
Publicado: (2023)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rl59f8to8qs5t70inqrmtksral